Alvin Shih, Retrophin’s (NASDAQ: RTRX) executive vice president and head of R&D, will leave the San Diego-based company at the end of the month. Shih has taken an offer to be the CEO of an unidentified biotech startup.
From Our Editors · Special Report
The cutting-edge companies behind the innovations disrupting biopharma and revolutionizing the healthcare landscape
Sponsored · Webinar
This new paradigm may well define a next dimension of precision medicine
Eurofins Discovery
From Our Partners · Special Report
Advice for funding and future transformational opportunities
